Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Ovarian cancer is the deadliest gynecological cancer which rarely causes symptoms, and goes undetected until reaching the advanced stage of drug-resistant metastases. The cationic porphyrin meso-tetra(4-N-methylpyridyl)porphine (TMPyP) is a well-known photosensitizer (PS) used in photodyamic therapy (PDT) for curing cancer due to its strong affinity for DNA and high yield of reactive oxygen species (ROS) upon light activation. The practicality to irradiate tumor cells alone in the physiological system being slim (due to the close proximity of healthy cells and tumors), we looked for a variation in the PDT using a mixture of TMPyP with 1,5-dihydroxynapthalene (DHN) and Fe(III) ions at a mole ratio of 1:20:17 (drug combo) respectively in aqueous solution. The drug combo needs no photoactivation in HO rich environment (mimicking the microenvironment of cancer/tumor), where it generates ȮH and juglone, the latter being a known potent anticancer agent. In vitro studies of the drug combo in drug resistant and sensitive ovarian cancer cell lines showed drastic growth inhibition and cell death compared to normal epithelial cells. The drug combo provides an effective and non-invasive alternative to conventional PDT, exploiting the cytosolic carcinogenic HO to produce an efficient anticancer treatment. The unique action of cancer-specific cytotoxicity arises from the redox chemistry involving activation of Fe(III) as the oxidizing agent to generate juglone, which utilizes the cytosolic ROS in cancer cells against itself.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959003 | PMC |
| http://dx.doi.org/10.1016/j.bbrc.2022.01.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of oral afoxolaner (NexGard®) against natural infestations with Heterodoxus spiniger (Phthiraptera: Boopiidae) in dogs under field conditions.
Vet Parasitol Reg Stud Reports
August 2025
Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007 Lyon, France.
Heterodoxus spiniger is a chewing louse of a diverse range of hosts, primarily Carnivora. Domestic dogs are considered a major host, and infestations can lead to pruritus, hair loss, or seborrhea. In the context of absence of clinical trials evaluating the efficacy of isoxazolines against H.
View Article and Find Full Text PDFImpaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.
Cells
July 2025
Unitat d'Atenció Crohn-Colitis, Servei d'Aparell Digestiu, Hospital Universitari Vall d'Hebron, CP 08035 Barcelona, Spain.
: Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. : We prospectively evaluated humoral and cellular immune responses at short-term (4-6 weeks) and long-term (6-12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4-6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination.
View Article and Find Full Text PDFLigand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation.
Nat Commun
August 2025
State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Auranofin, an FDA-approved antirheumatic gold drug, has gained ongoing interest in clinical studies for treating advanced or recurrent tumors. However, gold ion's dynamic thiol exchange nature strongly attenuates its bioactivity due to the fast formation of covalent albumin-gold adducts. Here we report that newly-added thiols can modulate the dynamic albumin-gold binding and recover the therapeutic efficacy.
View Article and Find Full Text PDFAssociation Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.
Diabetes Ther
September 2025
Futata Tetsuhiro Clinic, Fukuoka, Japan.
Introduction: This study assessed whether early weight loss following tirzepatide treatment was associated with clinical characteristics and outcomes at 52 weeks in Japanese patients with type 2 diabetes (T2D).
Methods: Post hoc analyses used pooled data from the phase 3 SURPASS J-mono and J-combo studies, which examined tirzepatide 5, 10, and 15 mg as monotherapy or combination therapy in Japanese participants over 52 weeks. Subgroup analyses of clinical characteristics and metabolic outcomes at 52 weeks were conducted based on early weight loss achievement of < 5% or ≥ 5% after 8 weeks of tirzepatide (comprising 4 weeks each at 2.
Objectives: To assess treatment and identify predictive factors of worsening in COVID-19 patients.
Methods: This study was ambispective (both prospective and retrospective) and part of a multidisciplinary, multicenter project designed to generate epidemiological, sociological and anthropological data about the COVID-19 epidemic in Burkina Faso. Medical records of patients admitted for COVID-19 at the hospitals of Ouagadougou and Bobo-Dioulasso from March 2020 to April 2021 were reviewed.